CNS Pharmaceuticals, Inc. Common Stock (CNSP) Stock Price
CNSPStock
$5.80−8.33%52W
Market Cap$8.48M
P/E—
PEG Ratio—
Div yield—
Beta1.06
CNSP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)75.55%
Price vs S&P 500 (4W)14.11%
VGM Score63.83
CNSP Earnings Surprise History
Q2 25-6.42est. -9.60
Q3 25-5.76est. -6.63
Q4 25-10.15est. -5.09
Q1 26-7.30est. -5.37
CNSP Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNSPCNS Pharmaceuticals, Inc. Common Stock | — | — | B | $5.80 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About CNS Pharmaceuticals, Inc. Common Stock
CNS Pharmaceuticals is a clinical-stage biopharmaceutical company developing anticancer therapies for brain and central nervous system tumors. The company's lead candidate, Berubicin, is in development for glioblastoma, an aggressive form of primary brain cancer with limited treatment options. The company aims to address significant unmet medical needs in oncology.